MHRA raises concerns with switching between long-acting J&J, Novartis and Takeda ADHD drugs

The U.K. drug regulator has told healthcare professionals to exercise caution when considering switching between long-acting attention-deficit/hyperactivity disorder (ADHD) therapies from companies including Johnson & Johnson, Novartis and Takeda.